LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Home・Lista de Ações・Ovid therapeutics Inc

Ovid therapeutics Inc

Fechado

SetorSaúde

2.4 0.42

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

2.31

Máximo

2.46

Indicadores-chave
By Trading Economics
Rendimento	-27M -17M
EPS	-0.125
Margem de lucro	-2,366.017
Funcionários	23
EBITDA	-5.5M -18M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+122.08% upside

Dividendos
By Dow Jones
Próximos Ganhos	12 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-5M 478M
Abertura anterior	1.98
Fecho anterior	2.4

Sentimento de Notícias

By Acuity

92%

5 / 344 Ranking em Healthcare

Ovid therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de jun. de 2026, 23:22 UTC

Ganhos

Grandes Movimentos do Mercado

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 de jun. de 2026, 23:09 UTC

Ações em Alta

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 de jun. de 2026, 20:51 UTC

Ganhos

Costco Reports 15% Sales Growth in May

3 de jun. de 2026, 20:43 UTC

Ganhos

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 de jun. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 de jun. de 2026, 23:48 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 de jun. de 2026, 23:35 UTC

Conversa de Mercado

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 de jun. de 2026, 23:15 UTC

Conversa de Mercado

Ganhos

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 de jun. de 2026, 22:08 UTC

Ações em Alta

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 de jun. de 2026, 21:54 UTC

Conversa de Mercado

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 de jun. de 2026, 21:18 UTC

Ganhos

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 de jun. de 2026, 21:15 UTC

Ganhos

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 de jun. de 2026, 21:13 UTC

Ganhos

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 de jun. de 2026, 21:13 UTC

Ganhos

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 de jun. de 2026, 21:12 UTC

Ganhos

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 de jun. de 2026, 21:09 UTC

Ganhos

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 de jun. de 2026, 21:03 UTC

Ganhos

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

3 de jun. de 2026, 20:43 UTC

Ganhos

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 de jun. de 2026, 20:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 de jun. de 2026, 20:37 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 de jun. de 2026, 20:35 UTC

Ganhos

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 de jun. de 2026, 20:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 de jun. de 2026, 20:17 UTC

Ganhos

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 de jun. de 2026, 20:17 UTC

Ganhos

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 de jun. de 2026, 20:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 de jun. de 2026, 20:15 UTC

Ganhos

Broadcom 2Q Adj EPS $2.44 >AVGO

3 de jun. de 2026, 20:15 UTC

Ganhos

Broadcom 2Q EPS $1.91 >AVGO

3 de jun. de 2026, 20:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

3 de jun. de 2026, 20:15 UTC

Ganhos

Broadcom 2Q Rev $22.19B >AVGO

Comparação entre Pares

Variação de preço

Ovid therapeutics Inc Previsão

Preço-alvo

By TipRanks

122.08% parte superior

Previsão para 12 meses

Média 5.33 USD 122.08%

Máximo 7 USD

Mínimo 4 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Ovid therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

Comprar

Manter

Vender

Com base em 8 analistas que deram avaliações de ações para Ovid therapeutics Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

5 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.